- Global Pharma News & Resources

SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

PR Newswire

JERSEY CITY, N.J., Aug. 29, 2018

JERSEY CITY, N.J., Aug. 29, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in the following upcoming investor conferences:

  • Baird's 2018 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, September 5, 2018 at 2:00 p.m. ET.
  • The H.C. Wainwright 20th Annual Global Investment Conference at the St. Regis New York on Thursday, September 6, 2018 at 12:30 p.m. ET.
  • The Oppenheimer Fall Summit at the Langham, New York, Fifth Avenue on Wednesday, September 26, 2018.

A live webcast of the Baird and HC Wainwright presentations will be available on the Investors section of the Company's website: Replay of the presentations will be available approximately two hours after each event and will be available for two weeks following each presentation.

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit


Investor Relations
Natalie Wildenradt
Argot Partners
Tel: 212-600-1902

Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093

View original content:


Editor Details

Last Updated: 29-Aug-2018